Boston Scientific (NYSE:BSX) (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales. Its product categories include devices and systems for interventional cardiology and peripheral interventions, electrophysiology and rhythm-management therapies, endoscopy and digestive health, as well as solutions for urology and pelvic health and neuromodulation for pain management. The company emphasizes catheter-based, implantable and endoscopic technologies designed to improve patient outcomes and reduce recovery times.
The company operates and sells products globally, serving hospitals, health systems and physician practices across North America, Europe, Asia-Pacific and other international markets. Boston Scientific maintains research and development and manufacturing capabilities in multiple countries and routinely engages in clinical trials and partnerships with medical centers and physicians to support product adoption and regulatory approvals.
As a publicly traded company, Boston Scientific is governed by an executive management team and board of directors that pursue a strategy combining internal innovation, clinical evidence generation and selective acquisitions to expand its product portfolio. The company continues to prioritize investment in R&D and collaboration with the medical community to advance minimally invasive treatment options.
